Ohr Pharmaceuticals, Inc. (NASDAQ:OHRP) has received a consensus broker rating score of 3.00 (Hold) from the one brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation. Ohr Pharmaceuticals’ rating score has declined by 200% from three months ago as a result of various analysts’ ratings changes.
Analysts have set a 1-year consensus price target of $0.40 for the company, according to Zacks. Zacks has also assigned Ohr Pharmaceuticals an industry rank of 169 out of 265 based on the ratings given to related companies.
OHRP has been the subject of a number of analyst reports. Zacks Investment Research lowered shares of Ohr Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 11th. Roth Capital initiated coverage on shares of Ohr Pharmaceuticals in a report on Monday, November 27th. They set a “buy” rating and a $7.00 target price for the company. Finally, ValuEngine upgraded shares of Ohr Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, December 1st.
Ohr Pharmaceuticals (NASDAQ OHRP) traded down $0.02 during trading on Friday, hitting $0.37. 7,937,700 shares of the stock were exchanged, compared to its average volume of 4,110,000. The stock has a market capitalization of $20.59, a price-to-earnings ratio of -0.63 and a beta of 0.48. Ohr Pharmaceuticals has a one year low of $0.35 and a one year high of $2.18.
TRADEMARK VIOLATION NOTICE: “” was published by Watch List News and is owned by of Watch List News. If you are viewing this report on another domain, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright legislation. The original version of this report can be accessed at https://www.watchlistnews.com/1800501-2/1800501.html.
About Ohr Pharmaceuticals
OHR Pharmaceutical, Inc, a pharmaceutical company, focuses on the development of novel therapeutics and delivery technologies for the treatment of ocular disease. Its lead clinical program is topical Squalamine, a small molecule anti-angiogenic drug, which could provide a non-invasive therapy to enhance vision outcomes.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Ohr Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ohr Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.